Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experienceSophie Park, François Dreyfus, Valérie Coiteux et al.|Blood|2007Cited by 332
Improved Outcome of Acute Promyelocytic Leukemia With High WBC Counts Over the Last 15 Years: The European APL Group ExperienceCharikleia Kelaïdi, Lionel Adès, Sylvie Chevret et al.|Journal of Clinical Oncology|2009Cited by 120
Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomideCharikleia Kelaïdi, Pierre Fenaux, Sophie Park et al.|Leukemia Research|2008Cited by 78